《结核病政策指南制订过程中发现的证据和研究缺口(第2版)》解读OA北大核心CSTPCD
Interpretation of Evidence and research gaps identified during development of policy guidelines for tuberculosis(Second edition):tuberculosis related comorbidity
应对结核病患者共病和相关危险因素对于终止结核病流行至关重要.世界卫生组织2023年发布了《结核病政策指南制订过程中发现的证据和研究缺口(第2版)》,其中,关于结核病相关共病方面,主要列出了结核分枝杆菌/HIV双重感染、营养支持与关怀,以及注射吸毒人群等方面的研究缺口.本文中,笔者就上述研究缺口内容进行解读,并总结我国目前在上述方面的研究进展,以供相关专业工作者参考.
Addressing comorbidities and associated risk factors in patients with tuberculosis is crucial for eradicating the disease.In 2023,the World Health Organization released the second edition of Evidence and research gaps identified during development of policy guidelines for tuberculosis,which highlights the principal research gaps in tuberculosis-related comorbidities,notably in Mycobacterium tuberculosis/HIV co-infection,nutritional support and care,and among populations of injecting drug users.In this article,the author interprets these identified research gaps and summarizes China's current research advancements in these areas,providing insights for professionals engaged in related fields.
刘桂珍;邓国防
赣南医科大学第一临床医学院,赣州 341000深圳市第三人民医院/国家感染性疾病临床医学研究中心/广东省结核病临床医学研究中心/深圳市结核病临床医学研究中心,深圳 518000
临床医学
结核共病现象总结性报告(主题)
TuberculosisComorbiditySummary report(topic)
《中国防痨杂志》 2024 (006)
618-624 / 7
国家自然科学基金(82070016);国家重点研发计划(2023YFC2306700;2023YFC2306703);广东省结核病临床医学研究中心项目(2020B1111170014);深圳市结核病临床研究中心(20210617141509001);深圳市科创委基金(KCXFZ20211020163545004;RCJC20221008092726022);深圳市第三人民医院科研基金(G2021010;G2021015;G2021023;G2022155) National Natural Science Foundation of China(82070016);National Key Research and Development Program of China(2023YFC2306700;2023YFC2306703);Guangdong Provincial Clinical Research Center for Tuberculosis Project(2020B1111170014);Shenzhen Clinical Research Center for Tuberculosis(20210617141509001);Shenzhen Scientific and Technological Foundation(KCXFZ20211020163545004;RCJC20221008092726022);Shenzhen Third People's Hospital Research Fund(G2021010;G2021015;G2021023;G2022155)
评论